The U.S. Department of State’s Office of the Assistant Secretary for Health
(OASH) is currently accepting applications from eligible entities for
its program titled “FY17 National Lupus Outreach and Clinical Trial Education Program” under “Minority Health Community Programs to Improve Minority Health”.
Lupus is an autoimmune disease that causes a host of symptoms and poses significant disease management and
treatment challenges for patients and health care providers. In
autoimmune disorders such as lupus, the immune system, which is designed
to protect against infection, creates auto antibodies that attack the
body’s own tissues and organs. These auto antibodies cause inflammation
which damages organs and tissue. Although science has made significant
advances in the treatment and management of this disease, there is still
no cure for lupus. In the United States, lupus disproportionately affects African Americans, Asians, and American Indians. People of African Caribbean
or African descent may also be at higher risk. Lupus is two to three
times more common in African American populations. The age range for
individuals with lupus also varies widely. Lupus can occur in very young
children or the elderly; however, the average age range for diagnosis of lupus is generally between 15 and 44. In this age group, women
with lupus outnumber men 12 to 1. Because these are childbearing years,
the impact of lupus on women is particularly problematic.
National efforts to increase minority participation in clinical trials have been underway for the past
twenty-five years, and recent evidence suggests that progress has been
made in all phases of clinical trial research. To foster participation,
researchers have explored barriers to participation such as patient
mistrust, access to care, and perceptions of providers. Patient mistrust
of medical research among minority populations, especially among
African Americans, has been well documented. Patient beliefs that
physicians might not fully explain the details of participation or would
allow participation in clinical trials even if serious harm were
possible is evidence that providers play a pivotal role in clinical
trial participation. Access to health care, especially lack of insurance
coverage, has also been suggested as a reason for lack of participation
in clinical trials.
Program will accomplish the following goals:
The estimated total funding allotted to this program is $2,000,000, with award ceiling of up to $325,000 and award floor of up to $250,000.
The following entities are eligible to apply:
How to Apply
Applications must be submitted online via given website.
Eligible Country: United States
For more information, please visit Grants.gov.